SEC Form 4 research
| Issuer | ACTUATE THERAPEUTICS, INC. |
|---|---|
| Tickers | ACTU |
| Reporting owners | 39 |
| Officers and directors | 7 |
| Last public filing | 2026-11-02 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-11-02 | 2026-10-28 | DEMETRIADES JAMES T, Kairos SPV Fund LLC, Kairos Venture Investments, LLC, Kairos Venture Opportunities I, L.P., Kairos Venture Partners II, L.P., Kairos-Actuate SPV, L.P., THOMSON TODD S | A | 95,673 | Not reported | Not reported |
| 2026-11-02 | 2026-10-28 | DEMETRIADES JAMES T, Kairos SPV Fund LLC, Kairos Venture Investments, LLC, Kairos Venture Opportunities I, L.P., Kairos Venture Partners II, L.P., Kairos-Actuate SPV, L.P., THOMSON TODD S | A | 75,738 | Not reported | Not reported |
| 2026-11-02 | 2026-10-28 | DEMETRIADES JAMES T, Kairos SPV Fund LLC, Kairos Venture Investments, LLC, Kairos Venture Opportunities I, L.P., Kairos Venture Partners II, L.P., Kairos-Actuate SPV, L.P., THOMSON TODD S | A | 259,572 | Not reported | Not reported |
| 2026-11-02 | 2026-10-28 | DEMETRIADES JAMES T, Kairos SPV Fund LLC, Kairos Venture Investments, LLC, Kairos Venture Opportunities I, L.P., Kairos Venture Partners II, L.P., Kairos-Actuate SPV, L.P., THOMSON TODD S | A | 269,017 | Not reported | Not reported |
| 2026-10-30 | 2026-10-28 | BIOS Fund III NT, LP, BIOS Fund III QP, LP, BIOS Fund III, LP | A | 269,342 | $0 | Not reported |
| 2026-10-30 | 2026-10-28 | BIOS Fund III NT, LP, BIOS Fund III QP, LP, BIOS Fund III, LP | A | 36,056 | $0 | Not reported |
| 2026-10-30 | 2026-10-28 | BIOS Fund III NT, LP, BIOS Fund III QP, LP, BIOS Fund III, LP | A | 82,018 | $0 | Not reported |
| 2026-10-30 | 2026-10-28 | BIOS Fund III NT, LP, BIOS Fund III QP, LP, BIOS Fund III, LP | A | 47,972 | $0 | Not reported |
| 2026-10-30 | 2026-10-28 | BIOS Fund III NT, LP, BIOS Fund III QP, LP, BIOS Fund III, LP | A | 368,304 | $0 | Not reported |
| 2026-10-30 | 2026-10-28 | BIOS Fund III NT, LP, BIOS Fund III QP, LP, BIOS Fund III, LP | A | 194,984 | $0 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.